Anticipate clinical safety and MFM32 functional data for TSHA-120 from the highest dose cohort of 3.5x1014 total vg in GAN in
Expect preliminary clinical safety data and Hex A enzyme activity in the plasma and cerebral spinal fluid for TSHA-101 in GM2 gangliosidosis in
Anticipate preliminary clinical data for the first-generation construct in CLN7 disease including safety data from first patient ever dosed intrathecally at 1.0x1015 total vg in
On track to initiate Phase 1/2 trials for TSHA-118 in CLN1 disease and TSHA-102 in Rett syndrome by year-end 2021
Completed five successful concurrent GMP campaigns for multiple programs to date, sufficient to support clinical-stage programs this year
Received Orphan Drug Designation from the
Successfully completed nine regulatory meetings with multiple agencies to support clinical trial initiations; submitted initial request for end-of-Phase meeting to align regulatory pathway for TSHA-120 in giant axonal neuropathy (GAN)
Recent publications of positive preclinical data from an AAV-mediated UBE3A gene replacement approach for Angelman syndrome and TSHA-104 for the treatment of SURF1-associated Leigh syndrome further support clinical development strategies
Conference call and live webcast today at
“We made significant advances in multiple aspects of our business, including nine productive regulatory meetings across several programs, a strategic addition of the clinical-stage CLN7 program and publication of positive preclinical data related to the Angelman syndrome and SURF1-associated Leigh syndrome programs,” noted RA Session II, President, Founder and CEO of Taysha. “In September, we submitted an end-of-Phase meeting request for TSHA-120 with a major ex-US regulatory agency and look forward to submitting additional requests to multiple regulatory agencies by the end of this year. In GAN, we have up to 6 years of longitudinal data in individual patients and collectively 55-patient years of clinical safety and efficacy data from our ongoing clinical study. We also have eight years of robust longitudinal data from a natural history study being conducted at the
“We believe the combination of our experience in gene therapy drug development, clinical pipeline and a strong balance sheet provides us with the financial and operational flexibility to achieve numerous value-generating milestones across our programs, and importantly, a potential regulatory approval for TSHA-120 in GAN in the near term. We look forward to continued execution on our development and regulatory strategies, and will provide updates throughout the remainder of this year,” concluded
Recent Corporate Highlights
-
Publication of AAV-mediated UBE3A gene replacement approach for the treatment of Angelman syndrome in the
Journal of Clinical Investigation Insight (JCI Insight) -
Sponsored genetic testing for giant axonal neuropathy (GAN) in partnership with
GeneDx, Inc to support inclusion of the genetic marker for GAN in theGeneDx hereditary neuropathy panel at no cost to individuals at risk for or suspected of having GAN -
Announced collaboration with
Hereditary Neuropathy Foundation andCharcot-Marie-Tooth Association Centers of Excellence to increase GAN disease awareness and access to testing - Obtained an exclusive option from UT Southwestern (UTSW) to license worldwide rights to a clinical-stage AAV9 gene therapy replacement program for the treatment of CLN7 disease
- Entered into a research collaboration with UTSW to develop a next-generation construct for the treatment of CLN7 disease, which is expected to improve potency, safety profile, packaging efficiency and manufacturability over the first-generation construct
- Provided a grant to Batten Hope, the leading CLN7 patient advocacy group, to support patient education, disease awareness and newborn screening initiatives
- Announced publication of positive preclinical data for TSHA-104 demonstrating therapeutic potential in SURF-1-associated Leigh syndrome in Molecular Therapy: Methods & Clinical Development
- Completed five successful concurrent GMP campaigns for multiple programs to date, sufficient to support clinical-stage programs this year. 187,000 square foot internal manufacturing facility on track to be fully operational in 2023
-
Received Orphan Drug Designation from the
European Commission for TSHA-105 for SLC13A5-related epilepsy, TSHA-102 for Rett syndrome and TSHA-101 for GM2 gangliosidosis -
Hosted CLN1 Investor Day on
August 30 th highlighting the company’s TSHA-118 program- TSHA-118-treated CLN1 knockout mice demonstrated persistent supraphysiological levels of active PPT1, improved survival rates and sustained preservation of motor function
- Insights from Key Opinion Leaders on preclinical data, utility of natural history data and current clinical trial design
-
Hosted Rett Syndrome Investor Day on
September 22 nd highlighting the company’s TSHA-102 program- miRARE reduced overall expression of miniMeCP2 transgene expression and regulated genotype-dependent myc-tagged miniMECP2 expression across different brain regions on a cell-by-cell basis
- Reviewed preclinical and natural history data that support an anticipated IND/CTA filing
-
Hosted Angelman Syndrome Investor Day on
October 26 th highlighting the company’s two-pronged approach to treating Angelman syndrome- Two therapeutic approaches target entire Angelman syndrome population using gene replacement strategy on UBE3A to mimic the maternal UBE3A allele expression and a vectorized knockdown of UBE3A-ATS to unsilence the paternal allele
- AAV-mediated UBE3A gene replacement recapitulates endogenous isoform ratios by replacing both the short and long isoforms of UBE3A in key regions of the brain, leading to improvements in motor learning, behavior outcomes, and seizure phenotypes in Angelman mouse models
Anticipated Milestones by Program
TSHA-120 for GAN: an intrathecally dosed AAV9 gene therapy currently being evaluated in a clinical trial for the treatment of GAN, a rare inherited genetic disorder that affects both the central and peripheral nervous systems and is caused by loss-of-function mutations in the gene coding for gigaxonin
-
Based on a longitudinal prospective natural history study conducted at the
NIH by Dr. Carsten Bönnemann, there is a predictable decline in the MFM32 score of approximately 8-points per year across all patients regardless of age. A 4-point change in MFM32 is considered clinically meaningful. To date, we have up to eight years of robust data from this study. - Currently in the GAN program, we have up to 6 years of longitudinal data in individual patients and collectively 55-patient years of clinical safety and efficacy data from our ongoing clinical study with no drug-related serious adverse events, no signs of acute or subacute inflammation, no sudden sensory changes and no drug-related or persistent elevation of transaminases
- In December, anticipate clinical safety and functional MFM32 data for TSHA-120 from the highest dose cohort of 3.5x1014 total vg in GAN, with continued clinically meaningful slowing of disease progression similar to that achieved with the lower dose cohorts would be considered confirmation of disease modification
-
Request for end-of-Phase meeting with ex-US regulatory agency for TSHA-120 completed in September with a preliminary meeting date in
January 2022 . Additional submissions expected by the end of 2021 - Finalized plan for commercial grade material and initiated development of comparability protocol to support BLA/MAA filing
TSHA-101 for GM2 gangliosidosis: the first bicistronic gene therapy in clinical development designed to deliver two genes –
- Based on natural history data, 2% to 4% Hex A enzyme activity in plasma normalizes survival and significantly improves clinical phenotype of GM2 gangliosidosis
- Preclinical data demonstrated intrathecal delivery of TSHA-101 was safe and well-tolerated in GM2 knockout mice
-
Expect preliminary clinical safety data and HEX A enzyme activity in plasma and CSF for TSHA-101 in GM2 gangliosidosis in
December 2021 from ongoing Canadian study, where Hex A enzyme activity level of at least 5% in plasma would be considered disease modifying based on natural history data - Due to severity of the disease and unmet medical need, currently assessing the need for US study to support regulatory filing
AAV9 Gene Replacement for CLN7 disease: an investigational AAV9 intrathecally dosed gene replacement therapy designed to deliver a full-length copy of the CLN7 gene to potentially treat CLN7 disease, a rapidly progressing rare lysosomal storage disease with no approved treatments. The first-generation construct is currently in clinical development with the next-generation construct anticipated to have improved potency, safety, packaging efficiency and manufacturability.
- Toxicology studies in wild type rodents demonstrated safety and tolerability of intrathecal administration of the first-generation construct across all dose levels and time points
-
Preliminary clinical safety data for the first patient in history to be intrathecally dosed at 1.0x1015 total vg with the first-generation construct expected by
December 2021 - Completion of next-generation construct by year-end 2021, with initiation of a planned pivotal trial in 2022 using next-generation construct with reference to human proof-of-concept clinical data generated from the first-generation construct
- Commercial-grade GMP material for next-generation construct expected in 2022
TSHA-118 in CLN1 disease: a self-complementary AAV9 viral vector designed to express a human codon-optimized CLN1 transgene to potentially treat CLN1 disease, a rapidly progressing rare lysosomal storage disease with no approved treatments
- Preclinical data demonstrated that TSHA-118 was safe and well tolerated following intrathecal administration in CLN1 knockout mice
- In preclinical models, TSHA-118-treated mice demonstrated supraphysiological levels of active PPT1 enzyme with no associated adverse effects, suggesting a wide therapeutic window for clinical dosing
- Currently open IND
- Additional CTA filing submitted
- Initiation of a Phase 1/2 clinical trial by year-end 2021
- Preliminary clinical safety and PPT1 enzyme activity data expected in first half of 2022
TSHA-102 in Rett syndrome: a self-complementary AAV9 gene therapy in development for a severe neurodevelopmental disorder, designed to deliver miniMECP2, as well as a novel miRARE platform that regulates transgene expression genotypically on a cell-by-cell basis
- In preclinical animal models, intrathecal myc-tagged TSHA-102 was not associated with early death and did not cause adverse behavioral side effects in wild type mice demonstrating appropriate downregulation of miniMECP2 protein expression as compared to unregulated MECP2 gene therapy constructs
- Preclinical data demonstrated that miRARE regulated transgene expression genotypically on a cell-by-cell basis and improved the safety of TSHA-102 without compromising efficacy in juvenile mice
- Recently obtained pharmacology data demonstrated improvement in survival, and respiratory and motor functions in disease relevant mouse models. Data to be shared at a later date
- Preliminary data from a GLP toxicology study in non-human primates demonstrated no adverse findings at the highest dose tested suggesting that the miRARE platform is successfully downregulating MECP2 expression to within normal physiological levels
-
Submission of IND/CTA filing in
November 2021 - Initiation of Phase 1/2 clinical trial by year-end 2021
- Preliminary clinical data expected by year-end 2022
Third Quarter 2021 Financial Highlights
Research and Development (R&D) Expenses: Research and development expenses were
General and Administrative (G&A) Expenses: General and administrative expenses were
Net loss: Net loss for the three months ended
Cash and cash equivalents: As of
Conference Call and Webcast Information
Taysha management will hold a conference call and webcast today at
About
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” “plans,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning the potential of our product candidates, including our preclinical product candidates, to positively impact quality of life and alter the course of disease in the patients we seek to treat, our research, development and regulatory plans for our product candidates, the potential for these product candidates to receive regulatory approval from the FDA or equivalent foreign regulatory agencies, and whether, if approved, these product candidates will be successfully distributed and marketed, the potential market opportunity for these product candidates, and our corporate growth plans. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our
|
|
||||||||||||||||
|
Condensed Consolidated Statements of Operations |
||||||||||||||||
|
(in thousands, except share and per share data) |
||||||||||||||||
|
(Unaudited) |
||||||||||||||||
|
For the Three Months
|
For the Nine Months
|
|||||||||||||||
|
2021 |
2020 |
2021 |
2020 |
|||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development |
$ |
39,528 |
|
$ |
11,057 |
|
$ |
94,025 |
|
$ |
19,633 |
|
||||
| General and administrative |
|
11,153 |
|
|
3,984 |
|
|
29,518 |
|
|
5,002 |
|
||||
| Total operating expenses |
|
(50,681 |
) |
|
15,041 |
|
|
123,543 |
|
|
24,635 |
|
||||
| Loss from operations |
|
(50,681 |
) |
|
(15,041 |
) |
|
(123,543 |
) |
|
(24,635 |
) |
||||
| Other income (expense): | ||||||||||||||||
| Change in fair value of preferred stock tranche liability |
|
- |
|
|
- |
|
|
- |
|
|
(17,030 |
) |
||||
| Interest income |
|
37 |
|
|
- |
|
|
143 |
|
|
- |
|
||||
| Interest expense |
|
(543 |
) |
|
(1 |
) |
|
(737 |
) |
|
(28 |
) |
||||
| Total other expense, net |
|
(506 |
) |
|
(1 |
) |
|
(594 |
) |
|
(17,058 |
) |
||||
| Net loss |
$ |
(51,187 |
) |
$ |
(15,042 |
) |
$ |
(124,137 |
) |
$ |
(41,693 |
) |
||||
| Net loss per common share, basic and diluted |
$ |
(1.35 |
) |
$ |
(1.28 |
) |
$ |
(3.31 |
) |
$ |
(3.73 |
) |
||||
| Weighted average common shares outstanding, basic and diluted |
|
38,003,954 |
|
|
11,733,170 |
|
|
37,495,537 |
|
|
11,176,429 |
|
||||
|
|
||||||||
|
Condensed Consolidated Balance Sheet Data |
||||||||
|
(in thousands, except share and per share data) |
||||||||
|
(Unaudited) |
||||||||
|
|
|
|||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents |
$ |
188,785 |
|
$ |
251,253 |
|
||
| Prepaid expenses and other current assets |
|
8,385 |
|
|
6,626 |
|
||
| Total current assets |
|
197,170 |
|
|
257,879 |
|
||
| Restricted cash |
|
2,628 |
|
|
- |
|
||
| Deferred lease asset |
|
691 |
|
|
715 |
|
||
| Property, plant and equipment, net |
|
40,553 |
|
|
287 |
|
||
| Total assets |
$ |
241,042 |
|
$ |
258,881 |
|
||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities | ||||||||
| Accounts payable |
$ |
22,051 |
|
$ |
1,994 |
|
||
| Accrued expenses and other current liabilities |
|
21,163 |
|
|
5,135 |
|
||
| Total current liabilities |
|
43,214 |
|
|
7,129 |
|
||
| Build-to-suit lease liability |
|
26,607 |
|
|
- |
|
||
| Term Loan, net |
|
27,812 |
|
|
- |
|
||
| Other non-current liabilities |
|
3,015 |
|
|
450 |
|
||
| Total liabilities |
|
100,648 |
|
|
7,579 |
|
||
| Stockholders' equity | ||||||||
| Preferred stock, |
|
- |
|
|
- |
|
||
| Common stock, |
|
- |
|
|
- |
|
||
| Additional paid-in capital |
|
325,657 |
|
|
312,428 |
|
||
| Accumulated deficit |
|
(185,263 |
) |
|
(61,126 |
) |
||
| Total stockholders’ equity |
|
140,394 |
|
|
251,302 |
|
||
| Total liabilities and stockholders' equity |
$ |
241,042 |
|
$ |
258,881 |
|
||
View source version on businesswire.com: https://www.businesswire.com/news/home/20211110005629/en/
Company Contact:
SVP, Corporate Communications and Investor Relations
klee@tayshagtx.com
Media Contact:
carolyn.hawley@canalecomm.com
Source: